Age-Specific Differences in Duration of Clinical Protection After Vaccination With Meningococcal Polysaccharide a Vaccine

Reingold, ArthurL.; Hightower, A. W.; Bolan, GailA.; Jones, E. E.; Tiendrebeogo, H; Broome, C V; Ajello, GloriaW.; Adamsbaum, C.; Phillips, Chris; Yada, Adamou

doi:10.1016/s0140-6736(85)90224-7

Cited by 224 publications

(73 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Vaccines directed against the serogrouping antigen, the capsular polysaccharide, are effective against some meningococci (Gotschlich et al, 1969;Jennings & Lugowski, 1981), but poor immunological reactivity and immunological similarity to host antigens has hampered the development of such vaccines against serogroup B meningococci, which are responsible for most disease in Europe, North and South America and Australasia (Finne et al, 1983;Reingold et al, 1985;Wyle et al, 1972). Outer-membrane proteins (OMPs) are major candidates in the search for alternative vaccine components either in purified form (Boslego et al, 1995) or as part of complex outer-membrane vesicle (OMV) formulations (Bjune et al, 1991;Claassen et al, 1996).…”

Section: Introductionmentioning

confidence: 99%

Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component

2003

View full text Add to dashboard Cite

Meningococcal FetA (FrpB), an iron-regulated outer-membrane protein and vaccine component, was shown to be highly diverse: a total of 60 fetA alleles, encoding 56 protein sequences, were identified from 107 representative Neisseria meningitidis isolates. Phylogenetic analysis established that the allelic variants had been generated by both point mutation and horizontal genetic exchange. Nucleotide substitution was unevenly distributed in the gene, which contained both conserved and variable sequence regions. The most conserved region of the translated peptide sequence corresponded to an amino-terminal domain of the protein and the most diverse region to a previously identified variable region (VR). A nomenclature system for the peptides encoded by the VR was devised which classified 24 variants into 5 FetA variant families. On the basis of these data, murine polyclonal sera specific for four FetA variants were generated. The reactivities of these sera in whole-cell ELISA experiments were consistent with the hypothesis that the VR encoded an immunodominant epitope and indicated that the sera reacted mainly with variants against which they were raised. The diversity of this protein is likely to limit its effectiveness as a vaccine component.

show abstract

Section: Introductionmentioning

confidence: 99%

Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component

2003

View full text Add to dashboard Cite

show abstract

“…9 Retrospective case-control studies conducted one, two and three years after vaccination in Burkina Faso indicated overall efficacy of 87% for year 1, 70% for year 2, and 54% for year 3. 10 By the third year, vaccine efficacy was only 8% for children immunized below four years of age, as compared with 67% for children immunized at four to 16 years of age.…”

Section: Discussionmentioning

confidence: 96%

Group A Antibody Persistence Five Years After Meningococcal Polysaccharide Vaccination in the Sudan

Flitter¹,

Ismail²,

Vu³

et al. 2007

Human Vaccines

View full text Add to dashboard Cite

“…In one study, group A vaccine efficacy in children immunized at younger than 4 years decreased from more than 90% to less than 10%; in children given vaccine at older than 4 years of age, vaccine efficacy was 67% 3 years later. 20 …”

Section: Duration Of Protectionmentioning

confidence: 99%

Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients

2005

Pediatrics

View full text Add to dashboard Cite

Two peaks in the incidence of invasive meningococcal disease (IMD) occur in pediatric patients: infants younger than 1 year and adolescents 15 to 18 years of age. Although the incidence of IMD is highest in infants, the case-fatality rate is highest in adolescents (∼20%). Epidemiologic studies also have demonstrated increased risk of IMD among college freshman living in dormitories compared with other college students and similarly aged persons in the general population. At least 75% of cases of IMD in 11- to 18-year-olds are caused by serogroups A, C, Y, and W-135; thus, IMD potentially is preventable by immunization with quadrivalent meningococcal vaccines. Meningococcal A, C, Y, W-135 conjugate vaccine (MCV4) was licensed in 2005 for use in people 11 to 55 years of age. On the basis of data indicating increased risk of meningococcal disease and fatality among certain adolescents and college students, the American Academy of Pediatrics recommends administration of MCV4 to young adolescents (at the 11- to 12-year visit), students entering high school or 15-year-olds, and college freshmen who will be living in dormitories. For pediatric patients 11 years and older who are at increased risk of meningococcal disease, MCV4 also is recommended. The purposes of this statement are to provide the rationale for routine use of MCV4 in adolescents and to update recommendations for use of the meningococcal polysaccharide vaccine in pediatric patients.

show abstract

Age-Specific Differences in Duration of Clinical Protection After Vaccination With Meningococcal Polysaccharide a Vaccine

Cited by 224 publications

References 10 publications

Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component

Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component

Group A Antibody Persistence Five Years After Meningococcal Polysaccharide Vaccination in the Sudan

Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients

Contact Info

Product

Resources

About